Indivior Dividend

Dividend criteria checks 0/6

Indivior zahlt derzeit keine Dividende.

Key information

Dividend yield

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	UK£0.015
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Indivior (LON:INDV) Shareholders Have Enjoyed An Impressive 153% Share Price Gain

Dec 20

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von INDV in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von INDV gestiegen sind.

Dividend Yield vs Market

Indivior Dividend Yield vs Market

How does INDV dividend yield compare to the market?
Segment	Dividend Yield
Company (INDV)	0%
Market Bottom 25% (GB)	2.2%
Market Top 25% (GB)	6.0%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (INDV)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von INDV im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von INDV im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: INDV zahlt keine nennenswerte Dividende für den Markt UK.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da INDV keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Indivior Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior (LON:INDV) Seems To Use Debt Quite Sensibly

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Investor sentiment deteriorated over the past week

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022

High number of new directors

Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC

Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Investor sentiment improved over the past week

Consensus forecasts updated

Indivior PLC, Annual General Meeting, May 05, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Indivior PLC, Annual General Meeting, May 05, 2022

Chief Human Resources Officer recently sold UK£428k worth of stock

Chief Scientific Officer exercised options and sold UK£1.5m worth of stock

Chief Commercial & Strategy Officer recently sold UK£810k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Indivior PLC Provides Revenue Guidance for the Year 2022

Indivior PLC to Report Fiscal Year 2021 Results on Feb 16, 2022

Indivior PLC Announces Results from Buprenorphine-Fentanyl Interaction Study in PLOS ONE

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: EPS US$0.04 (vs US$0.014 in 3Q 2020)

Indivior (LON:INDV) Seems To Use Debt Rather Sparingly

Investor sentiment improved over the past week

Independent Non-Executive Chairman recently bought UK£50k worth of stock

Second quarter 2021 earnings released: EPS US$0.08 (vs US$0.025 in 2Q 2020)